
# **Results for the** *H1 2024*

Jean-Yves Parisot (CEO), Olaf Klinger (CFO)

1 August 2024









01 H1 2024 at a Glance

## Financial highlights H1 2024

## Top and bottom-line figures show double digit growth






<sup>1</sup> Business Free Cash Flow = EBITDA – CapEx (including cash effects from leasing) +/- changes in Working Capital

<sup>2</sup> Adjusted for one-time effects

<sup>3</sup> Attributable to shareholders of Symrise AG

## **Sales H1 2024** *Strong organic growth*






## Sales by Segment H1 2024 Both Segments with high double-digit growth






## **Sales by region H1 2024** *Positive sales development in all regions*

#### **Organic growth by region** in %



#### Sales by region % of global sales





**Financials** 




## **Group H1 2024** Organic growth of 11.5 % (reported 6.3 %)



#### Sales development

In €m



**Organic growth of 11.5 % or €278m** driven by strong business in both segments.

**Negative sales contribution** from portfolio effect of €16m:

- Divestment of 51 % of Trading Business in UK, as of March 1, 2024

**Negative currency effects** of €110m, attributable to multiple currencies.

## Group H1 2024

## *Profitability positively impacted by product mix and efficiency improvements*

~ .

H1 2023	H1 2024	Change in %
2,414	2,565	6.3
879	998	13.5
36.4	38.9	2.5pp
475	530	11.5
19.7	20.7	1.0pp
85	110	29.5
59	54	-7.9
331	366	10.4
13.7	14.3	0.6pp
	2,414 879 36.4 475 19.7 85 59 331	2,4142,56587999836.438.947553019.720.7851105954331366

<sup>1</sup> H1 2023 normalized for one-time effects in segment S&C (€29.0m)

**Gross profit:** increased by 13.5 % due mainly to COGS growing by 2.1 % slower than sales. Slight improvement of material usage.

**EBITDA:** increased by €55.0m coming from profitable sales growth and strict cost measures, in connection with efficiency improvement program.

**Efficiency program:** Total identified saving potential of €50m for 2024. €25m already achieved in H1 2024. Starting point for ongoing future efficiency improvement

**EBITDA margin:** increased to 20.7 %, which is 1.0 pp above previous year's EBITDA margin<sup>1</sup>.

**EBIT:** increased by €35.0m being impacted from higher depreciation, which includes impairments of €17.9m on plants and machinery and assets under construction.

**EBIT margin:** increased to 14.3 %, which is 0.6 pp above previous year's EBIT margin<sup>1</sup>.




## Taste, Nutrition & Health H1 2024

Healthy growth and solid profitability

#### Sales development

In €m



#### Short P&L

ln €m

in € million		H1 2023	H1 2024	Change in %
EBITDA		334.9	347.6	3.8
EBITDA margin	in %	21.9	22.1	
EBIT		235.6	228.6	-2.9
EBIT margin	in %	15.4	14.5	

#### Organic growth of 10.0 % resulting from both divisions.

- **Food & Beverage** developed very positively with single digit-growth, driven by Savory, Sweet and Beverages. Negative Portfolio effect coming from divestment of Trading Business, UK.
- **Pet Food** with continued positive growth momentum

EBITDA margin: increased to 22.1 % - industry leading profitability.

**EBIT margin:** decreased to 14.5 % due to higher depreciation.




## Scent & Care H1 2024

## Strong double-digit growth in Fragrance and Cosmetic Ingredients

#### Sales development

In €m



#### Short P&L

In €m

in € million		H1 2023 <sup>1</sup>	H1 2024	Change in %
EBITDA		140.1	182.1	30.0
EBITDA margin	in %	15.8	18.3	
EBIT		95.8	137.1	43.1
EBIT margin	in %	10.8	13.8	

#### Organic growth of 14.1 % resulting from all divisions:


- Fragrance enjoyed double-digit sales growth in Fine Fragrances as well as Consumer Fragrance.
- Aroma Molecules sales development recovered significantly in H1 2024 due to resumption of production in Colonels Island.
- Cosmetic Ingredients posted double-digit growth driven by strong demand in Micro & Sun Protection.

**EBITDA margin:** amounts to 18.3 % - strong recovery against H1 2023.

**EBIT margin**: strong recovery to 13.8 %.

<sup>1</sup> H1 2023 normalized for one-time effects in segment S&C (€29.0m)

## **EPS H1 2024** Strong increase by 27.7 %



**Financial result:** €3m above 2023, mainly due to a slightly improved interest result and lower expenses associated with hyperinflation effects, mainly in Argentina.

**Income tax:** rate at 25.3 % within the tax guidance of 25-27 %.


**Net income:** €52m above previous year mainly due to improved profitability and negative one-time effects posted in H1 2023.

**EPS:** increased by 27.7 % to €1.71 per share.



## **Business Free Cash Flow (BFCF) development**

Reflects improvements in EBITDA and working capital



EBITDA (adjusted)

- Investments (including cash effects from leasing)

-/+ Changes in working capital

= Business Free Cash Flow



**BFCF of €226 million** (H1 2023: €106m) = 8.8 % (H1 2023: 4.4%) of sales

#### Improved EBITDA contribution


Slight decrease in **CAPEX from €97m** in H1 2023 to €92m.

**Working capital** development supported by improved inventory management.

**Ambition 2024** BFCF around 12 % of sales; mid term target of 14%

## **Net debt development** *Improved Net debt / EBITDA ratio*





Net debt (incl. pension provisions and leasing obligations) /EBITDA ratio

Net debt/EBITDA ratio

#### **Status Quo**

**Net debt** of €2,245m (2023: €2,166m) reflects 2.3 x EBITDA<sup>1</sup>.

Net debt including pension provisions and leasing obligation of €2,734m reflects 2.9 x EBITDA<sup>1</sup>.

#### Ambition

**Long-term target** of 2.0 to 2.5 x EBITDA (incl. pensions provisions and leasing obligation).

Unchanged since IPO.


Priority: Remain investment grade profile.

## Equity ratio<sup>1</sup> of 48.2 %


Assets

ln €m

Balance sheet H1 2024



#### Equity and Liabilities In €m




#### Comments

Increase in **assets** primarily from higher trade receivables, offset by a decrease in cash and lower inventories.

Changes to **equity and liabilities** mainly resulted from an increase in retained earnings.

**Equity ratio**<sup>1</sup> at a healthy level of 48.2 % (2023: 47.0%).



## 03 Strategic Initiatives / Outlook

## Taste, Nutrition & Health

### Innovation, capabilities and divestment

#### Digital Immersion Co-Creation Center in Singapore

To drive end-to-end co-creation with customers and industry partners



**Divestment of Aqua Feed** Business does not fulfill portfolio strategy anymore. Sales ~€20m p.a.



New Offices and Labs in Beijing, China Creation and Application

for Food & Beverage



**Sustainability Pet Food** Operation teams in different sites working on efficiency (Scope 1+2)



Launch of Nutritional and Health products at VitaFoods





**GlucoZen** Supports blood glucose levels

GutBalancebodSupports gutlshealth





HappyBellyVSupportsSupportsdigestive healthin

VitaPro Supports immunity

China: -15 % Electricity Multiple initiatives such as cold stream production

**Brazil: -8 % Energy** Technology improvement in spray dryingl

France: -14 % Water Through in process control

## Scent & Care Innovation and capabilities

#### Vizag Care **Ingredients India**

Expansion of geographical footprint in cosmetic ingredients in Asian JY

### **LAUTIER 1795**

Accelerating Lautier's singularity. Integrated floral expertise

**New Fragrance Facility in Grasse** R&D, Production and Cocreation on Natural extracts (Q1 2025)



.....

MET GALA 2024

**EXHIBITION** 



gamma



Met Gala 2024 Fine Fragrance Award at **World Perfumery Congress** received

**HOLZMINDEN LAB® Unique fragrance ingredients** 

\_EXPERT IN RENEWABLE WOOD DERIVATIVES NATURAL SOURCES NOT COMPETING FOOD CROPS

MASTERING THE ART OF UPCYCLING

+30+2

INIMITABLE CAPTIVE MOLECULES created for high impact & low carbon footprint NEW CAPTIVE MOLECULES To be launched in 2024: FROSTWOOD AMBRONOV



HOLZMINDEN LAB.



HOLZMINDEN LAB.





symrise 😭

symrise 🕄

## Symrise's integrated corporate strategy

Sustainability along the value chain






Strong alignment with UN Sustainability Goals

## **Targets 2024** *Confident to achieve objectives*

#### Targets 2024



**Corporate view** Business environment fully intact with high industry dynamics

Taste, Nutrition & Health Building competencies towards complementary business areas

Scent & Care Strong capabilities in fragrances and cosmetic ingredients

> **Execution of an efficiency program** aiming for higher profitability

## Long-term financial objectives 2028

*Symrise continues with ambitious financial targets* 



Financial targets	until <b>2025</b>	until <b>2028</b>
Sales (€ bn) Organic sales growth (CAGR)	5.5 – 6.0 5 – 7%	7.5 – 8.0 5 – 7%
Sales growth incl. M&A (CAGR)	6 – 9%	8 – 10%
EBITDA margin	20 – 23%	20 – 23%
Business Free Cash Flow	14%	14%



always inspiring more

## Symrise AG



## Financial calendar

**24 October 2024** 9M 2024 Trading statement

**19-20 November 2024** Symrise Capital Market Days Holzminden/Germany

### Contact

**Symrise AG** Muehlenfeldstraße 1 37603 Holzminden, Germany

**Tobias Erfurth** Investor Relations tobias.erfurth@symrise.com

IR@symrise.com

**Bernhard Kott** Corporate Communications and Chief Sustainability Officer bernhard.kott@symrise.com

This document contains forward-looking statements, which are based on the current estimates and assumptions by the corporate management of Symrise AG. Future performance and the results actually achieved by Symrise AG and its affiliated companies depend on a number of risks and uncertainties and may therefore differ materially from the forward-looking statements. Many of these factors are outside Symrise's control and cannot be accurately estimated in advance, such as the future economic environment and the actions of competitors and others involved in the marketplace. Symrise neither plans nor undertakes to update any forward-looking statements.